Skip to main content

Nutex Health, Inc. (NUTX) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $139.49 (+17.02%)

Consensus Target
$205.00
Upside
+47.0%
Analysts
Rating

Price Target Range

Low $205.00High $205.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Sep 18, 2024Anthony VendettiMaxim Group$45.00-67.7%

NUTX vs Sector & Market

MetricNUTXHealthcare AvgLarge Cap Avg
Analyst Rating2.242.41
Analyst Count818
Target Upside+47.0%+1150.2%+14.9%
P/E Ratio10.836.8631.19

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$204M$222M$245M3
2026-09-30$205M$222M$245M1
2026-12-31$221M$239M$264M2
2027-12-31$940M$947M$955M2

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$3.25$3.61$4.111
2026-09-30$3.19$3.55$4.031
2026-12-31$3.82$4.25$4.831
2027-12-31$16.79$17.55$18.621

Frequently Asked Questions

What is the analyst consensus for NUTX?

The consensus among 0 analysts covering Nutex Health, Inc. (NUTX) is — with an average price target of $205.00.

What is the highest price target for NUTX?

The highest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.

What is the lowest price target for NUTX?

The lowest price target for NUTX is $45.00, set by Anthony Vendetti at Maxim Group on 2024-09-18.

How many analysts cover NUTX?

0 analysts have issued ratings for Nutex Health, Inc. in the past 12 months.

Is NUTX a buy or sell right now?

Based on 0 analyst ratings, NUTX has a consensus rating of — with a +47.0% upside to the consensus target of $205.00.

What are the earnings estimates for NUTX?

Analysts estimate NUTX will report EPS of $3.61 for the period ending 2026-06-30, with revenue estimated at $222M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.